Amgen
Amgen and UCB announce positive romosozumab results
February 22, 2016Medical Communications, Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, osteoporosis
Romosozumab development partners Amgen and UCB have announced positive top-line results from a Phase III study of the drug in postmenopausal …
Amgen’s Kyprolis now available to UK multiple myeloma patients
February 12, 2016Medical Communications, Sales and Marketing Amgen, Kyprolis, multiple myeloma
Amgen has announced the UK launch of Kyprolis (carfilzomib) in combination with Revlimid (lenalidomide) and dexamethasone for the treatment of …
EMA accepts Sandoz Neulasta biosimilar for review
February 11, 2016Research and Development Amgen, Neulasta, Novartis, Sandoz
Sandoz says the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for its proposed biosimilar to Amgen’s …
NICE changes mind on Amgen’s cholesterol drug
February 8, 2016Manufacturing and Production, Sales and Marketing Amgen, NICE, Repatha
NICE has changed its mind on Amgen’s cholesterol-busting drug Repatha (evolocumab), and decided to recommend approval of the treatment in …
FDA to review Amgen’s Humira biosimilar
January 26, 2016Manufacturing and Production ABP-501, Amgen, FDA, biosimilar
The FDA has accepted for review Amgen’s Biologics License Application (BLA) for ABP 501, a biosimilar candidate to AbbVie’s Humira …
Amgen earns first Japanese nod for PCSK9 inhibitor
January 25, 2016Sales and Marketing Amgen, Astellas, Japan, PCSK9 inhibitor, Repatha, evolocumab, high cholesterol
The Japanese Ministry of Health, Labour and Welfare has approved Amgen’s cholesterol-lowering medication Repatha, in a joint venture between Amgen …
FDA approves new Kyprolis combo for multiple myeloma
January 22, 2016Medical Communications, Sales and Marketing Amgen, FDA, Kyprolis, carfilzomib, multiple myeloma, myeloma
Amgen’s Kyprolis has been given another endorsement by the FDA as a multiple myeloma treatment – its second in six …
Baxalta’s Enbrel biosimilar measures up in late-stage study
January 13, 2016Research and Development Amgen, Baxalta, Enbrel, Pfizer, biosimilar, etanercept, rheumatoid arthritis
Having emerged from its mega-merger deal with Shire, Baxalta is back on its drug development day job – and has …
Big pharma joins President Obama’s cancer ‘moonshot’
January 13, 2016Research and Development Amgen, Cancer, Celgene, National Immunotherapy Coalition, President Barack Obama, US, moonshot
Celgene and Amgen are among the large biopharma companies that have agreed to join the National Immunotherapy Coalition (NIC), a …
European approval for Amgen cancer drug Imlygic
December 18, 2015Sales and Marketing Amgen, European Commission, Imlygic, melanoma, skin cancer, t-vec, talimogene laherparepvec
The European Commission has approved the use of Amgen’s Imlygic for adults with advanced melanoma, making it the first drug …
Amgen buys back rights to three drugs from GSK
December 15, 2015Research and Development, Sales and Marketing Amgen, GSK
Amgen has announced that it will reacquire the rights to three products in 48 countries from GSK, as it seeks …
ASH 2015 roundup: Amgen, MorphoSys, Novartis and Roche present new trial data
December 8, 2015Research and Development Amgen, Cancer, Novartis, Roche, ash, morphosys, oncology
Amgen Amgen presented data from three Phase II trials evaluating Blincyto (blinatumomab) in acute lymphoblastic leukemia (ALL)- a rare and …
Amgen’s Kyprolis doubles Velcade benefit in head-to-head study
December 5, 2015Research and Development, Sales and Marketing Amgen, Cancer, Kyprolis, Takeda, Velcade, multiple myeloma
Amgen has announced that its multiple myeloma therapy Kyprolis displayed superiority to Takeda’s Velcade in the Phase III ENDEAVOR study …
Novartis and Amgen drugs signed-off by European Commission
November 24, 2015Manufacturing and Production Amgen, Entresto, European Commission, Novartis, blincyto
The European governing body, the European Commission, has approved the Novartis drug Entresto for heart failure and Amgen’s Blincyto for …
NICE rejects Amgen’s Repatha in draft guidance
November 18, 2015Research and Development, Sales and Marketing Amgen, NICE, Repatha, evolocumab, high cholesterol
NICE has published draft guidance rejecting Amgen’s Repatha as a treatment for people with high cholesterol.
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
